PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer

被引：10

作者：

Akiki, Mira ^{[1
]}

Haddad, Fady Gh ^{[2
]}

Kourie, Hampig Raphael ^{[2
]}

Khaddage, Abir ^{[1
]}

Smayra, Viviane Track ^{[1
]}

机构：

[1] St Joseph Univ, Fac Med, Pathol Dept, Beirut, Lebanon

[2] St Joseph Univ, Fac Med, Hematol & Oncol Dept, Beirut, Lebanon

来源：

BIOMARKERS IN MEDICINE | 2019年 / 13卷 / 18期

关键词：

breast cancer; clinical trials; immunotherapy; oncology; PD-L1; TNBC; triple negative; EXPRESSION;

D O I：

10.2217/bmm-2019-0344

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：1539 / 1541

页数：3

共 12 条

[11] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer [J].

Schmid, P. ;

Adams, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Barrios, C. H. ;

Iwata, H. ;

Dieras, V. ;

Hegg, R. ;

Im, S. -A. ;

Wright, G. Shaw ;

Henschel, V. ;

Molinero, L. ;

Chui, S. Y. ;

Funke, R. ;

Husain, A. ;

Winer, E. P. ;

Loi, S. ;

Emens, L. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22) :2108-2121

[12] Histology versus cytology: PD-L1 testing in non-small cell lung cancer [J].

Takigawa, Nagio ;

Ochi, Nobuaki ;

Yamane, Hiromichi .

TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 :S225-S227

← 1 2 →